Navigation Links
Surveyed U.S. Rheumatologists are Moderately Satisfied with Biologic Agents and Xeljanz to Treat Rheumatoid Arthritis
Date:10/30/2013

EXTON, Pa., Oct. 30, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. rheumatologists are moderately satisfied with the currently available biologic agents as well as Pfizer's Xeljanz for the treatment of rheumatoid arthritis (RA). Physicians have a strong preference for the more established, market-leading TNF-alpha inhibitors, Amgen/Pfizer's Enbrel and AbbVie's Humira, over other biologic agents and Xeljanz.  Surveyed physicians rated Enbrel and Humira highest in product satisfaction, perceive these agents as having the most favorable benefit/risk profiles, and they indicate that both products outperform other TNF-alpha inhibitors on the most important stated attributes to prescribing RA therapies. Consequently, these two biologic therapies are used typically as first- or second-line biologic treatment after conventional disease-modifying antirheumatic drug (DMARD) therapy failure.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

The TreatmentTrends®:Rheumatoid Arthritis (US) report finds that rheumatologists participating in this study also rated Xeljanz, the newest entrant in the RA market, moderately. However, Xeljanz was rated significantly lower than all biologics on overall product performance. In addition, Xeljanz has yet to carve out a distinct place in the RA treatment algorithm. Physicians reported using the product most often after one to three TNF-alpha inhibitor failures. The report also finds that only 14 percent of Xeljanz patients were biologic naive.

"Xeljanz was on the market 9 months at the time this study was fielded, so rheumatologists may not be certain as to which patient types would benefit most from Xeljanz, which is why they are trying it on different patient types at various points in the treatment algorithm," said BioTrends Senior Director Greta Unger. "A relatively low percentage of Xeljanz patients were biologic naive even though it has been approved for use in this patient group. It will be interesting to see if physicians' behavior changes over time as they gain more experience with the product."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. More than a Third of Chronic Kidney Disease-Non-Dialysis Patients are Likely Candidates for FG-4592/ASP1517, According to Surveyed EU5 Nephrologists
2. At One Month Post-Launch, Nearly a Quarter of Surveyed U.S. Oncologists Have Prescribed Tafinlar for Malignant Melanoma, Compared to 15 Percent Who Used Mekinist
3. Should Mircera Reach the U.S. Market, Surveyed Nephrologists State that at Least 40 Percent of CKD-ND and Dialysis Patients are Likely Candidates
4. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
5. Surveyed U.S. Neurologists Report Greater Overall Satisfaction with Tecfidera than with Platform Injectables and Other Oral Multiple Sclerosis Therapies
6. At One Month Post-Launch, Nearly One-Quarter of Surveyed U.S. Medical Oncologists Have Prescribed Xofigo to Their Prostate Cancer Patients
7. A Significant Share of Surveyed Treatment-Naive and Prior Failure HCV Patients Plan to Initiate an HCV Treatment Regimen in the Next Year
8. Surveyed U.S. Neurologists Are More Likely Than Payers to Consider Biogen Idecs Tecfidera to be a Breakthrough in the Treatment of Multiple Sclerosis
9. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
10. The Majority of Surveyed Oncologists Prescribe Avastin Off-label to Their Ovarian Cancer Patients; However Approximately Half Encounter Access and Reimbursement Hurdles
11. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2017)... , July 31, 2017  Diplomat Pharmacy, Inc. (NYSE: ... southeast Michigan by Crain,s Detroit ... private and public companies by three-year revenue growth. This year,s ... To view the complete list, visit ... 50 is an incredible triumph," said Phil Hagerman , ...
(Date:7/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results for ... updated its financial outlook for fiscal 2017. ... quarter, Hill-Rom reported earnings of $0.09 per diluted share ... period. These results reflect after-tax special items, including a ... the non-cash write-down of assets associated with the planned ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
Breaking Medicine Technology:
(Date:8/20/2017)... ... 2017 , ... State Farm Neighborhood Assist® has named The Southern Maryland ... grant. If the initiative wins, Gals Lead – Dream Queen Foundation’s signature teen girl ... of St. Mary’s, Calvert and Charles Counties. The program could potentially impact nearly 17,500 ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... will feature the Aurum Group in an upcoming episode, slated to air fourth ... Innovations will feature the Aurum Group; a company committed to supporting dentistry using ...
(Date:8/19/2017)... ... August 18, 2017 , ... Paragon and ... database to help the cannabis industry move towards greater legitimacy. By incorporating IOTA’s ... faster technology with lower fees. Paragon will build a fully verifiable database to ...
(Date:8/19/2017)... ... August 19, 2017 , ... The digital health and ... with pending recognition status from the Centers for Disease Control and Prevention (“CDC”) ... and live video conferencing. , The DPP resulted from clinical work conducted ...
(Date:8/19/2017)... ... 2017 , ... Praeclarus Press has launched a new ... the diversity of the breastfeeding mothers, using bright colors and contemporary themes. These ... are also available on tote bags, notepads, smartphone cases, clocks, and travel mugs. ...
Breaking Medicine News(10 mins):